Novo Nordisk's GLP-1 pill has reignited the competition in the GLP-1 space. But you can sidestep that drama by buying this surgical robotics pioneer.

Intuitive Surgical sees international procedures jump 23% in 2025, now 35% of total, outpacing U.S. growth and reshaping its long-term expansion strategy.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Intuitive Surgical dominates the robotic surgery market. The company sells surgical platforms, accessories, and service contracts.

Exploring the Latest 13F Filing and Investment Strategies Mairs and Power (Trades, Portfolio) recently submitted their 13F filing for the fourth quarter of 202

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical is the 800-pound gorilla in the robotic surgery realm. It has more than 11,000 systems installed worldwide.

Fifth Third Bancorp trimmed its position in Intuitive Surgical, Inc. (NASDAQ: ISRG) by 6.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 216,929 shares of the medical equipment provider's stock after selling 15,604 shares during the period. Fifth Third Bancorp owned 0.06% of Intuitive

Assetmark Inc. boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ: ISRG) by 3.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 55,521 shares of the medical equipment provider's stock after purchasing an additional 1,614 shares during

Intuitive Surgical balances 22% EPS growth with heavier 2026 R&D and expansion spending, betting near-term margin pressure will fuel long-term demand.